Accretion/Dilution and Merger Consequences

Once price, synergies, and consideration are settled, the analytical question changes: no longer what the target is worth, but what the deal does to the buyer. Merger consequences analysis answers that in four dimensions: the effect on earnings per share (accretion/dilution), the split of ownership in the combined company (contribution and exchange ratio analysis), the combined balance sheet (purchase price allocation), and the combined credit profile (pro forma credit analysis). A fifth output, the fairness opinion, converts the valuation work into a formal document the board relies on when it approves the transaction.

Accretion/dilution is among the most heavily tested M&A concepts in interviews, and everything else in this article hangs off it. Learn the mechanics from first principles, then the shortcuts, then trace the same deal through the balance sheet and the rating agencies' lens, because the structure that looks best on EPS is frequently the one that looks worst on credit.

The Accretion/Dilution Framework

A deal is accretive when the pro forma combined EPS exceeds the acquirer's standalone EPS, and dilutive when it falls below. The core comparison:

Expressed as a percentage of the starting point:

The verdict is an accounting outcome, not a judgment on deal quality. A strategically transformative acquisition can be dilutive in Year 1 and heavily accretive by Year 3, and a mechanically accretive deal can destroy value if the buyer overpaid. But boards, shareholders, and research analysts scrutinize the number because EPS is the metric most directly tied to the stock price, so it shapes deal approval, the form of consideration, and the public narrative.

Building Pro Forma EPS in Seven Steps

1. 1.Start with the acquirer's standalone net income, from LTM figures or consensus NTM estimates.
2. 2.Add the target's net income: the earnings being acquired, and the primary source of accretion.
3. 3.Subtract the after-tax financing cost: foregone interest income on balance sheet cash used, plus new interest expense on acquisition debt.
4. 4.Apply transaction adjustments: amortization of the intangibles created in the purchase price allocation (net of tax) and elimination of any intercompany revenue or expense between the two companies.
5. 5.Add after-tax synergies if they belong in the base case; whether to include them or show them only as a sensitivity depends on their certainty and the bank's convention.
6. 6.Compute pro forma shares: unchanged in a cash deal, acquirer shares plus new shares issued in a stock deal, and adjusted for the stock portion in a mixed deal.
7. 7.Divide combined net income by pro forma shares:

Every accretion/dilution question, no matter how dressed up, reduces to these seven steps: how much earnings arrive, what the funding costs after tax, and how many shares sit in the denominator.

A Full Worked Example

An acquirer has 500 million diluted shares at $100 each, $2.5 billion of net income, $5.00 of EPS, and trades at 20x P/E. It pays $10 billion for a target earning $700 million, funding half with balance sheet cash that was earning 4% pre-tax and half with new debt at 6%. The tax rate is 25%. The Year 1 build:

• •Target earnings contribution: +$700M
• •Foregone interest on cash: $5B x 4% x 0.75 = -$150M
• •New debt interest: $5B x 6% x 0.75 = -$225M
• •PPA amortization: roughly $3B of identifiable intangibles amortized over 10 years is $300M pre-tax, -$225M after tax
• •Synergies: $200M run-rate cost synergies at 30% Year 1 realization is $60M pre-tax, +$45M after tax

Pro forma net income is $2,500M + $700M - $150M - $225M - $225M + $45M = $2,645M. No shares were issued, so pro forma EPS is $2,645M / 500M = $5.29, which is 5.8% above the standalone $5.00: accretive in Year 1 even carrying the full PPA drag and only partial synergies. By Year 3, with full synergies ($150M after tax) and shorter-lived intangibles rolling off, accretion improves to roughly 10-12%.

Consideration and the Cost of Funding

The form of consideration is the single most powerful variable in the analysis because it sets both the cost side and the share count. Each funding source carries its own cost:

• •Cash on hand: the foregone after-tax interest income. $1 billion of cash that was earning 4% pre-tax costs $1B x 4% x (1 - 25%) = $30 million of net income per year.
• •New debt: the after-tax interest expense. $1 billion borrowed at 6% with a 25% tax rate costs $45 million annually.
• •Stock: no explicit financing cost. The cost is implicit in the larger denominator, because new shares dilute every existing holder.

For a cash or debt funded deal, where the share count does not move, the whole test collapses to one line:

If the target earns $100 million and the after-tax cost of the funding is $75 million, the deal adds $25 million of net income that flows straight into higher EPS.

The quick screen, before any model exists, compares the target's earnings yield (net income divided by purchase price) to the cost of what funds it. Cash deal: does the target yield more than the cash was earning after tax? Debt deal: does it yield more than the after-tax cost of the new debt? Stock deal: compare the two P/E ratios, which is the subject of the next section. In high-rate environments cash and debt look relatively cheap next to the implicit cost of stock, which is the acquirer's own earnings yield; the trade-off is that cash consumes balance sheet capacity.

Most large deals mix cash and stock, and the mix is an optimization problem. The banker runs the analysis at several ratios (100% cash, 75/25, 50/50, 25/75, 100% stock) and shows the board which structure produces the best EPS outcome; a deal that is dilutive at 100% stock can turn accretive at 50/50 when the after-tax cost of cash is below the implicit cost of shares. The same mix decision also drives the credit outcome, covered later, usually in the opposite direction.

The P/E Arbitrage Shortcut

For an all-stock deal there is a rule that requires no model at all. If the acquirer's P/E is higher than the target's P/E, the deal is accretive; if it is lower, the deal is dilutive. This is P/E arbitrage: the P/E is the price the market charges per dollar of earnings, so a 20x acquirer using its shares to buy a 12x target pays each dollar of target earnings with only about 60 cents of its own earnings (12/20). It receives more earnings per share than it gives up. "Arbitrage" is loose language, since nothing riskless is being captured, only a valuation differential in the exchange of securities.

The numbers make the logic concrete. An acquirer with a $10 billion market cap, $500 million of net income, and a 20x P/E buys a target with a $2 billion market cap, $200 million of net income, and a 10x P/E, all in stock at the target's market price. It issues $2 billion of new shares, growing its share count by 20%, while its earnings grow by 40% ($200M on $500M). Earnings grow faster than shares, so EPS rises. One reconciliation with real deals: the P/E that matters is the multiple actually paid, offer price over target earnings, so a premium raises the target's effective P/E and can flip a deal that looked accretive at the undisturbed price.

• •High P/E acquires low P/E (25x buys 12x): accretive, expensive currency buys cheap earnings
• •Equal P/Es (15x and 15x): neutral, the cost of shares equals the earnings received
• •Low P/E acquires high P/E (10x buys 22x): dilutive, cheap currency buys expensive earnings

The Crossover Price

The crossover price (or breakeven price) is the maximum purchase price at which the deal stays accretive; above it, dilution begins. For an all-stock deal, the crossover sits where the two earnings yields are equal:

For a debt-financed deal, it sits where the target's earnings exactly cover the after-tax interest:

Solving for the breakeven price of a target earning $90 million, funded with 6% debt at a 25% tax rate:

Above $2 billion, the deal turns dilutive. For mixed consideration the pure rule does not apply directly: assess the stock portion with the P/E comparison and the cash and debt portions with the yield-versus-funding-cost test, then combine.

What the Rule Does and Does Not Tell You

P/E arbitrage is mechanical, not strategic. A 25x acquirer buying a declining 12x business is accretive on paper while the acquired earnings erode underneath; a 10x company buying a 22x high-growth target is dilutive on paper while possibly making the combined business far more valuable. Accretion can also coexist with value destruction: a sufficiently high-P/E buyer can pay twice the target's market price and still print accretion, even though the premium may exceed anything synergies can justify. The dynamic still explains real patterns: highly rated companies become serial acquirers because every stock deal is automatically accretive, private-equity-backed roll-up platforms consolidate fragmented industries at lower multiples for immediate multiple arbitrage, and low-P/E incumbents buying high-P/E disruptors must defend the dilution on strategic grounds.

The Multi-Year View and the Limits of EPS Math

A complete analysis shows Years 1 through 3, not a single year, because many deals that are dilutive at close turn accretive as the combination matures. Three drivers shape the trajectory:

• •Synergy phasing: with cost synergies realized 30% / 70% / 100% over three years, a deal that is 3% dilutive in Year 1 can be 2% accretive in Year 2 and 8% accretive in Year 3.
• •Target growth: a target growing faster than the acquirer contributes a rising share of combined earnings each year.
• •PPA amortization wind-down: the non-cash drag fades as shorter-lived intangibles (customer relationships often carry 5-7 year lives) fully amortize.

A standard output alongside the trajectory is the breakeven synergy level: the annual synergies needed to make Year 1 EPS-neutral. If the deal is 5% dilutive without synergies and each $10 million of after-tax synergies adds roughly 1% of accretion, breakeven is about $50 million. The board compares that to the bottom-up synergy work: $150 million of credible identified savings against a $50 million breakeven is a wide margin of safety, while a $200 million breakeven against $100 million identified means the deal stays dilutive even on full delivery.

The limits of the metric matter as much as the mechanics. It is near-term and accounting-driven: it ignores strategic value, and the same acquisition can be accretive funded with cash and dilutive funded with stock even though the economics are identical. PPA amortization depresses EPS without touching cash flow, so a deal can be dilutive on a reported basis while strongly cash accretive; many companies present cash EPS, which excludes the non-cash amortization, alongside the reported figure. Boards accordingly accept Year 1 dilution when the deal is accretive by Year 2-3, when it is strategically transformative (Microsoft's $69 billion Activision Blizzard purchase and Facebook's $19 billion WhatsApp purchase were both dilutive at announcement), or when the target accelerates revenue growth enough that the market may re-rate the combined multiple. Communication is the other half: announcements of dilutive deals lead with the timeline to accretion and the synergy commitment, and the stock's reaction on announcement is the market's vote on whether the dilution is acceptable.

Presentation to the board compresses all of this into a page: the headline result ("X% accretive in Year 1, Y% by Year 3"), a sensitivity grid of accretion across purchase premium and synergy realization showing where the breakeven sits, the Year 1-3 trajectory, and the consideration mix comparison.

Contribution Analysis

Contribution analysis asks a different question from standalone valuation: not what each company is worth on its own, but what percentage of the combined entity each side represents across the metrics that matter. It is the primary framework in mergers of equals and a key check in any stock-for-stock deal where the target is large, because whoever contributes the earnings should own a corresponding share of the combination.

The output is a range, not a number: here Company A contributes 53-60% depending on the metric, and that range is the negotiation zone for the ownership split. Different metrics genuinely tell different stories. A high-revenue, low-margin company contributes more on revenue and less on EBITDA; a richly valued company contributes more on market cap than on net income. Each side's bankers push the metrics that flatter their client, but EBITDA and net income usually carry the most weight because they tie most directly to cash flow and to the multiples the market applies.

A true merger of equals has no clear buyer or seller: an ownership split near 50/50, a mixed board and management team, and no control premium. In practice most "mergers of equals" have a first among equals, splits land at 55/45 or 60/40, and the label is often marketing to soften the fact of being acquired. Two caveats sharpen the analysis:

• •Pure contribution assumes no premium. Target shareholders almost always receive at least a modest premium, which shifts the final split a few points in their favor relative to the raw contribution numbers.
• •Static metrics miss trajectory. Sophisticated versions run the analysis on forward metrics as well as LTM (a company growing EBITDA at 10% against a peer at 3% closes a 53/47 gap within two to three years), allocate synergies to the side whose cost base generates them, or use market caps to let the market's growth and risk assessment speak.

Contribution analysis and exchange ratio analysis are two halves of one negotiation: contribution determines the fair ownership split, and the exchange ratio is the mechanical instrument that delivers it. If contribution says 55/45 and share prices imply that a 0.85x ratio achieves it, the two must reconcile; when they diverge, one of the analyses gets revisited.

Exchange Ratio Analysis

In a stock-for-stock deal the target's shareholders are paid in acquirer shares, and the exchange ratio is the most negotiated term in the transaction:

If the target's undisturbed price is $40 and the agreed premium is 25%, the offer is $50 per share; against a $100 acquirer stock price the ratio is 0.50x, meaning each target share converts into half an acquirer share. The ratio simultaneously fixes the effective purchase price, the premium, and the ownership split, which is why every other analysis in this article gets cross-checked against it.

Fixed, Floating, and Collared Structures

The choice allocates the market risk between announcement and closing, a period that can run many months. Under a fixed exchange ratio, a 20% drop in the acquirer's stock is the target shareholders' problem; under a floating ratio, the acquirer must issue more shares to preserve the promised value. Collars come in two flavors: a walk-away collar keeps the ratio fixed while the acquirer's stock stays inside a band (say $70 to $90) and gives one side the right to terminate outside it, while an adjusting collar moves the ratio inside the band to hold a dollar value and locks it at the edges. Collar width is itself a signal: narrow suggests confidence, wide suggests valuation uncertainty.

Premium, Ownership, and the Underwater Ratio

The ratio and the premium are mechanically linked:

With a fixed ratio the realized premium floats with the acquirer's stock, and it can vanish. An underwater exchange ratio arises when the offer's market value falls below the target's standalone price: at 0.50x, an acquirer stock slide from $100 to $70 cuts the offer value from $50 to $35 per share, below a $40 undisturbed price. Underwater ratios drive renegotiations, trigger walk-away rights, or kill deals. The ratio also fixes who owns the combined company:

That ownership percentage should reconcile with the contribution analysis, premium included.

A full worked example ties the pieces together. The acquirer has 200 million shares at $80 (a $16 billion market cap); the target has 100 million shares at $40 (a $4 billion market cap); the agreed price is $52 per target share, a 30% premium. The exchange ratio is $52 / $80 = 0.65x, so 65 million new shares are issued, pro forma shares are 265 million, and target holders own 65/265 = 24.5% of the combination. That is consistent with the 20/80 market-cap contribution plus the premium effect. If the acquirer's stock slides to $65 before close, the offer value falls to $42.25 and the premium shrinks from 30% to 5.6%: renegotiation territory.

In the merger proxy, the fairness advisor tests the agreed ratio from several angles: the implied premium, sensitivity to both stocks' prices, ratios in precedent stock-for-stock deals, consistency with contribution benchmarks, and the historical exchange ratio analysis, which compares the agreed ratio to the market-implied ratio on each day of the prior twelve months. A ratio at the 75th percentile of that range supports fairness to the target; one at the 25th percentile invites the argument that its holders are being shortchanged.

The Pro Forma Balance Sheet and Purchase Price Allocation

The pro forma balance sheet is the combined entity's Day 1 snapshot: both companies' balance sheets merged, the purchase price allocated, and the financing layered in. It is a snapshot, not a projection, but every post-deal projection starts from it, so errors here compound through the whole model. Construction has three components: combine the balance sheets, apply the purchase price allocation (PPA), and apply the financing and transaction adjustments.

Combining and Allocating

Adding the two balance sheets line by line produces a raw combination that does not balance, because the target's equity has been bought and must be eliminated. The PPA resolves it. The target's tangible assets are marked to fair value (inventory and PP&E written up or down to appraised values), and new identifiable intangible assets are created for what the buyer actually paid for: customer relationships (usually the largest, valued with the multi-period excess earnings method, 5-15 year lives), trade names (valued by relief-from-royalty, sometimes indefinite-lived), developed technology (3-10 year lives), and favorable leases. Whatever purchase price remains after every identifiable asset and liability is recorded at fair value becomes goodwill:

Goodwill captures the unattributable residue: assembled workforce, going-concern value, market position, expected synergies. Under US GAAP (ASC 350) and IFRS (IAS 36) it is not amortized but tested annually for impairment; a write-down is a public admission of overpayment, as with Kraft Heinz's $15.4 billion impairment in 2019 and General Electric's roughly $22 billion of write-downs across 2018-2020. Goodwill above about half the purchase price signals elevated impairment risk. The target's historical equity, and its old goodwill, are eliminated and re-measured in the new allocation.

The Deferred Tax Liability

Writing assets up for book purposes while their tax basis carries over creates a deferred tax liability (DTL), because the future book depreciation and amortization on the write-up will never be tax deductible:

A $3 billion total write-up at a 25% tax rate creates a $750 million DTL. Because the DTL is an assumed liability, it reduces net identifiable assets, which makes the goodwill residual correspondingly larger.

The deal's tax structure decides whether that DTL exists at all. In a stock acquisition (the norm for public targets), tax basis carries over and the PPA intangibles are not tax deductible: book amortization with no tax shield. In an asset acquisition or a Section 338(h)(10) election (common in private M&A), the step-up applies for tax as well, intangibles amortize over 15 years under Section 197, and the resulting tax shield can be worth hundreds of millions in present value on a large deal. With book and tax basis aligned there is no step-up DTL, so asset deals typically show lower goodwill and better after-tax economics; the structure choice is driven primarily by tax.

Financing Adjustments and the Balance Check

The final layer records how the deal is paid for: new acquisition debt on the liability side, new equity (common stock and additional paid-in capital) for shares issued to target holders, cash reduced by the purchase price and by advisory, legal, and financing fees, and any refinancing of the target's existing debt. After everything, assets must equal liabilities plus equity; if not, the usual culprits are a target equity that was never eliminated, a mis-tracked cash impact, or goodwill computed as an untraceable plug. Each adjustment belongs in its own column with a supporting schedule. One recurring wrinkle is the negative cash problem: when the cash needed exceeds the combined balances, the model draws a revolver to restore cash to zero or a minimum operating level, and that draw is itself a new liability.

A compact illustration, simplified to ignore fair value write-ups and the DTL: acquirer assets of $15B plus target assets of $5B combine to $20B. The target's book equity was $2B but the buyer paid $8B; the $6B excess is allocated $2B to identifiable intangibles and $4B to goodwill, lifting total assets to $26B. Funding is $4B of new debt and $4B of new stock, the target's $2B of old equity is eliminated, and both sides balance at $26B.

Beyond balancing, the pro forma balance sheet feeds everything downstream: the leverage ratios for the credit analysis, pro forma tangible book value (equity minus goodwill and intangibles, the metric that matters for financial institutions), covenant compliance, and the PPA amortization that flows back into accretion/dilution (a $2 billion customer relationships intangible over 10 years is $200 million of annual amortization, a $150 million hit to net income at a 25% tax rate). One frequently missed item is the inventory step-up: marked-up inventory flows through COGS in the first quarter or two after close, so a $500 million inventory balance stepped up by 8% depresses EBITDA by $40 million, one-time and non-cash, which companies disclose and exclude from adjusted EBITDA.

Pro Forma Credit Analysis

A deal that is accretive to EPS but wrecks the acquirer's credit profile is not a good deal, and pro forma credit analysis is where that shows up. It evaluates the combined entity from the debt holders' and rating agencies' perspective: is the post-deal capital structure sustainable, do existing covenants survive, and does the rating hold. Four metrics carry the analysis:

• •Total Debt / EBITDA: the primary leverage measure. Investment-grade companies typically run below 3.0-3.5x; a debt-funded deal pushing past 4.0x risks a downgrade to high yield.
• •Net leverage ((Total Debt - Cash) / EBITDA): typically below 2.5-3.0x for investment grade.
• •EBITDA / Interest: coverage above 4.0-5.0x is comfortable; below 2.5-3.0x signals elevated default risk.
• •FFO / Debt: the agencies' preferred cash flow measure, with published thresholds by rating; above roughly 25-35% for investment grade.

The build is mechanical: pro forma debt is both companies' existing debt plus new acquisition debt minus anything repaid at close, and pro forma EBITDA is both EBITDAs plus synergies, for which agencies give only partial credit. Thresholds are industry-relative: regulated utilities with predictable cash flows can hold 4.0-5.0x at investment grade, consumer staples around 3.0-3.5x, technology 2.0-3.0x, and exploration-and-production energy just 1.5-2.5x, with qualitative factors (competitive position, diversification, management) shading the lines.

Why the Rating Matters

The consequences of a downgrade are concrete. A notch inside investment grade can widen borrowing spreads 50-100 basis points, which on $10 billion of debt is $50-100 million of extra annual interest. The cliff sits at the BBB-/BB+ boundary: a fallen angel faces forced selling from institutions barred from holding high yield, loses commercial paper access, and watches its lender base shrink, so companies at BBB- treat rating preservation as a constraint that can override strategy. Downgrades can also trip rating-linked provisions in existing agreements.

Form of consideration drives credit in the mirror image of how it drives EPS. All-cash funded with debt is the worst case: a $5 billion purchase adding $5 billion of debt against a target contributing $500 million of EBITDA is 10x incremental leverage blended into the acquirer's existing ratio. All-stock adds no debt and brings the target's EBITDA into coverage. Mixed structures are sized backward from the rating: if the agency's threshold for the current rating is 3.5x and all-cash lands at 4.2x, the banker solves for the mix that holds 3.3-3.4x with headroom. The advisory problem is optimizing accretion (favoring cash), credit (favoring stock), and the target's tax preference (often favoring stock for deferral) simultaneously.

Existing Covenants: The Hidden Constraint

Before announcement, lawyers and bankers sweep every covenant in the acquirer's existing debt, because the transaction itself can trip them:

• •Change of control provisions requiring repurchase offers on outstanding bonds
• •Incurrence tests in high-yield indentures that block new debt unless pro forma leverage or coverage passes a threshold, forcing consents or refinancing
• •Restricted payment baskets limiting how much balance sheet cash can fund the purchase
• •Most favored nation provisions that ratchet existing debt pricing up to match richer new acquisition debt

Any of these can reshape the financing structure, push the mix toward stock, or add a refinancing to the deal's timeline and cost.

Deleveraging and the Rating Agency Process

An investment-grade acquirer taking leverage above its range pairs the announcement with a deleveraging plan: a public commitment to return to target leverage within 18-24 months via free cash flow, asset sales, and sometimes a dividend cut, which is a powerful signal precisely because it redirects shareholder cash to debt paydown (and creates tension with income investors). A worked trajectory: a BBB industrial with $1 billion of EBITDA and $2.5 billion of debt (2.5x) buys a target for $3 billion, funded $2 billion debt and $1 billion stock, adding $300 million of EBITDA plus $50 million of run-rate synergies. Pro forma debt is $4.5B against $1.35B of EBITDA with full synergies: 3.3x at close (3.5x without synergies), at the upper edge of investment grade. The model then shows leverage stepping down as cash flow repays debt and synergies phase in, to roughly 2.8x in Year 1, 2.3x in Year 2, and 2.0x by Year 3. The trajectory's credibility rests on three assumptions the agencies test: the synergy timeline, the free cash flow conversion, and the dividend policy.

The process itself: some acquirers brief agencies confidentially before announcing; on announcement the acquirer typically goes on credit watch negative, and the review, usually resolved within a few weeks and formally within about 90 days, ends in an affirmation, a downgrade, or an affirmation with negative outlook. Agencies look past the base case at debt repayment capacity under a downside (EBITDA 10-20% below plan), the management team's integration track record, whether the deal improves the business profile (diversification, reduced cyclicality), and explicit financial policy commitments. Research notes that agencies sometimes extend a grace period to acquirers with credible plans, but that this leniency predicts a higher likelihood of eventual downgrade, and that issuers sitting at BBB- behave measurably more cautiously: longer deal timelines, more advisors, less debt financing, and lower-risk targets.

Fairness Opinions

A fairness opinion is where the valuation work in this guide meets corporate law: a formal written letter from an investment bank to a board of directors stating that the consideration in a proposed transaction is fair, from a financial point of view, to a specified stakeholder group. Directors approving a sale owe shareholders a fiduciary duty; the opinion is the documented evidence that they relied on independent financial analysis in discharging it. It is not legally mandated in most deals, but it is effectively required in management buyouts and going-private transactions (where management sits on both sides), in controlling-shareholder buyouts of minorities, and in most public company sales, because it materially reduces litigation risk.

Three Delaware cases frame the practice. Smith v. Van Gorkom (1985) held directors personally liable for approving a merger without adequate financial analysis and single-handedly created the modern fairness opinion market. Revlon (1986) established that once a company is for sale, the board's duty shifts to maximizing shareholder value; an opinion supports compliance with Revlon duties but cannot substitute for a real market check or sale process. In re Dell Technologies (2018-2024) ended in a $1 billion settlement with the opining bank named as a defendant, a reminder that the opinion exposes the bank itself to litigation years after closing.

Same Methods, Higher Standard

The analysis inside a fairness opinion is the standard toolkit: trading comps, precedent transactions, a DCF with sensitivities, an LBO analysis where financial buyers are relevant, a premium analysis against precedent premiums, and a football field synthesizing the ranges. What changes is the standard applied to it:

• •Documentation: every input (beta source, equity risk premium, peer selection criteria, terminal growth rate) must be supported well enough to survive cross-examination in a deposition, not just a reasonable pitchbook judgment.
• •Independent review: the opinion must clear the bank's fairness opinion committee, senior bankers and risk professionals independent of the deal team, who test methodology selection, assumption quality, whether the analysis actually supports the conclusion, and whether the documentation would withstand litigation. The committee can refuse to authorize the opinion; that is rare, but when it happens the deal terms usually get renegotiated.
• •Scope discipline: lawyers draft the limitations into the letter word by word.

The deliverable is two documents. The letter itself is typically one page, addressed to the board or its special committee of independent directors, and hedged with qualifications: it addresses only the financial fairness of the consideration, not whether the board should approve the deal or whether it is the best alternative; it relies on management's projections without independent verification; it speaks only as of its date; and the bank has no obligation to update it. Behind the letter sits the 30-50 page valuation presentation walking the board through each methodology and where the deal price falls against each range; the letter and analysis are filed with the merger proxy, where shareholders, and potentially courts, can examine them.

Be precise about what the opinion does not say, because interviewers test it: it does not say the price is the highest achievable, only that it falls within a financially fair range. A board can hold an opinion supporting $50 per share even if a more aggressive process might have produced $55. The opinion protects the board's process, not the outcome. The structural conflict is that the opining bank is usually the deal advisor, whose fee is largely contingent on closing, an arrangement that plainly rewards concluding "fair." Mitigants include mandatory proxy disclosure of the bank's fees and relationships, oversight by the special committee that retains the bank, and, in sensitive situations, a second bank engaged solely for the opinion on a flat, non-contingent fee. Boutique advisors (Evercore, Lazard, Centerview, Houlihan Lokey) have built franchises on that independence positioning; even so, the contingent single-advisor model remains the industry standard, because boards prefer an opinion from the bank that knows the deal best.